SCHEMBL17140752

SCHEMBL17140752

CN1CN(c2cccc(Cl)c2)C2(CCN(C(=O)OC(C)(C)C)CC2)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1L1 Q9UHC9 2/20 0.48
USP30 Q70CQ3 1/20 0.46
STS P08842 1/20 0.44
CCR5 P51681 3/20 0.44
ENPP2 Q13822 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
OPRK1 P41145 2/20 0.43
OPRL1 P41146 2/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
HTR2A P28223 1/20 0.43
DRD3 P35462 1/20 0.43
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
MAPK8 P45983 1/20 0.42
DDR1 Q08345 1/20 0.41
GPR119 Q8TDV5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17140692 0.88 NPC1L1 (0.58) NPC1L1USP30CCR5ENPP2OPRM1
SCHEMBL20187112 0.87 DDR1 (0.55) NPC1L1USP30STSCCR5ENPP2
SCHEMBL18940740 0.83 NPC1L1 (0.51) NPC1L1USP30CCR5ENPP2OPRM1
SCHEMBL17141075 0.82 NPC1L1 (0.48) NPC1L1USP30CCR5ENPP2OPRM1
SCHEMBL17141036 0.82 NPC1L1 (0.48) NPC1L1USP30CCR5ENPP2OPRM1
SCHEMBL17149558 0.82 NPC1L1 (0.48) NPC1L1USP30CCR5ENPP2OPRM1
SCHEMBL18940736 0.81 CCR5 (0.61) STSCCR5OPRM1OPRD1OPRK1
SCHEMBL17140776 0.81 NPC1L1 (0.47) NPC1L1STSCCR5OPRM1OPRD1
SCHEMBL17140743 0.81 NPC1L1 (0.54) NPC1L1USP30CCR5ENPP2OPRM1
SCHEMBL17149494 0.80 GPR119 (0.53) NPC1L1CCR5ENPP2OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190225611-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN X-RX, INC. 2019-07-25 US disclosed
US-10233182-B2 Substituted spirocyclic inhibitors of autotaxin X-RX, INC. (US) 2019-03-19 US disclosed
US-20180282332-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN X-RX, INC. 2018-10-04 US disclosed
US-10011601-B2 Substituted spirocyclic inhibitors of autotaxin X-RX, INC. (US) 2018-07-03 US disclosed
US-20170166568-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN X-RX, INC. (US) 2017-06-15 US disclosed
US-20170166568-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN X-RX, INC. (US) 2017-06-15 US disclosed
EP-3125895-A1 SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN X-RX, Inc. (US) 2017-02-08 EP disclosed
WO-2015154023-A1 SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN X-RX DISCOVERY, INC. (US) 2015-10-08 WO disclosed
WO-2015154023-A1 SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN X-RX DISCOVERY, INC. (US) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166568-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN ENPP2, SLC10A1, CXCR3 NPC1L1 497/4885USP30 4084/4885STS 545/4885
US-10233182-B2 Substituted spirocyclic inhibitors of autotaxin ENPP2, CXCR3, SLC10A1 NPC1L1 519/4885USP30 4105/4885STS 428/4885
US-20180282332-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN ENPP2, CXCR3, SLC10A1 NPC1L1 519/4885USP30 4105/4885STS 428/4885
US-20190225611-A1 SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN ENPP2, SLC10A1, CXCR3 NPC1L1 497/4885USP30 4084/4885STS 545/4885
US-10011601-B2 Substituted spirocyclic inhibitors of autotaxin ENPP2, SLC10A1, CXCR3 NPC1L1 497/4885USP30 4084/4885STS 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.